|
Sep 26
|
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully
|
|
Jul 11
|
One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year
|
|
Jul 9
|
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
|
|
Jun 26
|
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
|
|
May 9
|
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 6
|
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
|
|
May 1
|
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
|
|
Apr 13
|
VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans
|
|
Mar 19
|
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
|
|
Jan 10
|
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
|
|
May 1
|
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
|